Filing Flows › Health Care › Procept BioRobotics (PRCT)

Procept BioRobotics (PRCT) earnings and revenue breakdown

Latest: Q3 2026 · 10-Q filed Nov 4, 2026 · Procept BioRobotics (PRCT) Q3 2026 earnings results →

Q3 2026 Revenue up 18% year over year to $98.3M · 27¢ of every $1 of revenue lost · operating margin -27.9%

Procept BioRobotics made $98.3M in Q3 2026 (+18% Y/Y). Operating margin -27.9%, net loss $26.5M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 4, 2026.

Revenue$98.3M

Year over year+18%

Operating margin-27.9%

Net earnings−$26.5M

Operating cash flow−$9.0M

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

What changed this quarter

Revenue was $98.3M in Q3 2026, up 18% year over year and up 4% from the previous quarter.

Gross margin was 66.3%, up 1.5 points from Q3 2025. Operating costs exceeded revenue by $27.4M, an operating margin of -27.9%. Operating expenses grew 20% against revenue growth of 18%. The fastest-growing cost line was SG&A (+23%). The quarter ended with a net loss of $26.5M, narrower than the previous quarter's $26.9M loss.

Operating cash flow was −$9.0M. Non-cash charges added back $2.5M of depreciation and amortization and $15.1M of share-based compensation. Capital expenditures of $667K exceeded it, leaving free cash flow of −$9.7M.

Quarterly history

Quarter	Form	Filed	Revenue	Y/Y	Op. margin	Net earnings	Op. cash flow
Q3 2026	10-Q	Nov 4, 2026	$98.3M	+18%	-27.9%	−$26.5M	−$9.0M
Q2 2026	10-Q	Aug 5, 2026	$94.5M	+19%	-29.0%	−$26.9M	−$19.3M
Q1 2026	10-Q	Apr 30, 2026	$83.1M	+20%	-39.2%	−$31.6M	−$38.1M
Q4 2025	10-K	Feb 26, 2026	$76.4M	+12%	-40.6%	−$29.8M	−$10.3M
Q3 2025	10-Q	Nov 5, 2025	$83.3M	+43%	-27.8%	−$21.4M	−$6.6M
Q2 2025	10-Q	Aug 7, 2025	$79.2M	+48%	-28.0%	−$19.6M	−$15.0M
Q1 2025	10-Q	May 2, 2025	$69.2M	+55%	-39.7%	−$24.7M	−$17.0M

Charts

Latest (Q3 2026): Y/Y +18%, Q/Q +4%.

From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.

Latest (Q3 2026): Net income −$26.5M, Operating cash flow −$9.0M.

+26.4% since FY2020: more shares outstanding (issuance, stock pay); earlier years scaled for the 3-for-1 split before FY2022, 4-for-1 split before FY2021.

Cash $334M, short-term investments —, long-term debt $51.5M at 2024-12-31.

Surgical & Medical Instruments & Apparatus; dot size is quarterly revenue; dashed lines are the industry's medians.

Interactive views

The same charts as the app — open one to draw it.

💵Where each $1 goesinteractive

Loading the interactive chart…

🌏Named in Asian annual reportsinteractive

Loading the interactive chart…

🔄Rotation against the market and its industry (RRG)interactive

Loading the interactive chart…

🔍Earnings qualityinteractive

Loading the interactive chart…

⚖️Fair value by methodinteractive

Loading the interactive chart…

🔭Outlook & guidanceinteractive

Loading the interactive chart…

📈Investments: gains and what it boughtinteractive

Loading the interactive chart…

🏭Its industry’s money flow (input-output)interactive

Loading the interactive chart…

About Procept BioRobotics

We are a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. We develop, manufacture and sell the AquaBeam Robotic System and HYDROS Robotic System, which are advanced, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. Each of our robotic systems employs a single-use disposable handpiece to deliver our proprietary Aquablation therapy, which combines real-time, multi-dimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. We designed our robotic systems to enable consistent and reproducible BPH surgery outcomes.

In its own words, from its 10-K, filed Feb 26, 2026.

Procept BioRobotics against its Surgical & Medical Instruments & Apparatus peers

The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +18% against the peers' median +5%. Operating margin: -27.9% against the peers' median 13.3%.

Company	Quarter	Revenue	Y/Y	Op. margin
PRCT Procept BioRobotics	Q3 2026	$98.3M	+18%	-27.9%
MDLN Medline	Q3 2026	$7.9B	+10%	6.4%
MMM 3M	Q3 2026	$6.6B	+1%	23.7%
SYK Stryker	Q3 2026	$6.5B	+8%	15.9%
BSX Boston Scientific	Q3 2026	$5.1B	+1%	16.1%
BDX Becton Dickinson	Q3 FY26	$5.0B	+5%	13.3%
BAX Baxter International	Q3 2026	$3.0B	+5%	7.6%
SOLV Solventum	Q3 2026	$1.9B	-7%	3.5%
RMD ResMed	Q1 FY27	$1.4B	+6%	32.0%

Source: Procept BioRobotics 10-Q on SEC EDGAR · CIK 1588978 · Surgical & Medical Instruments & Apparatus

Guidance and outlook

20 statements; tone +0.45 (−1 all cautious, +1 all confident); 4 hedged.

13F: who owns PRCT and who is buying

Value of shares 13F filers added minus the value they sold, each quarter (quarters with most filings in).

More on PRCT

History

Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results

Compare PRCT with

中文版：Procept BioRobotics（PRCT）财报

Español · Français